Tapinarof

Dermavant Sciences reports positive long-term results for Vtama cream in treating plaque psoriasis and atopic dermatitis in adults and children as young as two. The ADORING 3 study showed 51.9% of patients achieved complete disease clearance, and 81.6% had clear or almost clear skin at least once. Vtama was well tolerated, with no loss of response, and the FDA is expected to decide on its approval for AD in Q4.

FDA approves expanded dosage for actinic keratosis drug, fourth ustekinumab biosimilar Otulfi approved in US and EU, FDA clears Accure’s laser system for acne, 320 mg bimekizumab pre-filled syringe and autoinjector approved, Health Canada approves roflumilast foam for seborrheic dermatitis, long-term results for ESK-001 in psoriasis, 40-week efficacy and safety of oral povorcitinib for prurigo nodularis, significant proportion of AD patients maintain stable EASI with tralokinumab, patients switching from dupilumab to upadacitinib achieve higher treatment targets in AD, final ECZTEND study confirms long-term safety and efficacy of tralokinumab, benvitimod is safe and effective for palmoplantar pustulosis, UCB announces head-to-head trial comparing bimekizumab and risankizumab, additional study confirms benzene presence in benzoyl peroxide products, LEO Pharma launches delgocitinib for chronic hand eczema in Germany, Almirall completes decentralized approval for efinaconazole in Europe, analyzing efficacy and safety in diverse clinical trials for roflumilast, disparities in hidradenitis suppurativa for skin of color populations, new treatments enhance care for diverse psoriasis patients.

James Del Rosso discussed new dermatology drugs at the Fall Clinical Dermatology Conference, including topical tapinarof 1% cream (Vtama) for psoriasis and potential atopic dermatitis, topical clascoterone (Winlevi) for acne, and nemolizumab (Nemluvio) for prurigo nodularis.

Roivant Sciences Ltd. (NASDAQ:ROIV) is a healthcare company with a market cap of $8.51 billion, focusing on drug development through technology and strategic partnerships. It ranks 2nd on a list of best small company stocks to invest in, with potential growth driven by successful clinical trials and strategic deals, such as a $1.2 billion deal for its Dermavant business. Analysts predict small-cap stocks, including ROIV, could benefit from lower interest rates and outperform large-cap stocks.

Organon plans to acquire Dermavant for up to $1.2 billion, gaining its commercialized plaque psoriasis drug Vtama, which is under FDA review for atopic dermatitis. Vtama sales grew to $75.1 million in FY2023, but face competition in a crowded market. Organon aims to leverage its global scale to expand Vtama's reach.